Recommend Cancer Biology & Therapy to your librarian for 2008. Download the form here.

Sign up for Table of Contents Alerts.

home subscribe search archive forthcoming

Email this page Print this page

Research Paper

Chimeric toxins inhibit growth of primary oral squamous cell carcinoma cells

Christopher Bachran, Iring Heisler, Diana Bachran, Katrin Dassler, Matthias F. Melzig, Jürgen Ervens and Hendrik Fuchs

volume 7 | issue 2

February 2008
Pages: 237 - 242

Purchase article for $19

Subscribe to this journal for $129/year

Treatment of oral squamous cell carcinoma (OSCC) is currently based on surgery and radiotherapy. Prolongation of the survival time of patients with progressing tumors is infrequently achieved. To improve the therapeutic options, targeted therapies are a favorable alternative. Therefore, we analyzed the effect of a chimeric toxin (CT) named SE consisting of the epidermal growth factor and the plant protein toxin saporin from Saponaria officinalis. A second construct (SA2E) additionally contains a peptidic adapter designed to enhance efficacy of the CT in vivo and to reduce side effects. The IC50 values for an oral squamous cell carcinoma cell line (BHY) were 0.27 nM and 0.73 nM for SE and SA2E, respectively, while fibroblasts remained unaffected. To investigate primary tumor cells, we developed a technique to analyze freshly prepared OSCC cells of 28 patients in a stem cell assay directly after surgery. Cells were treated for 1 h with the CTs, subsequently seeded into soft agar and colony growth determined after 1–2 weeks. In spite of the short time of CT incubation, the amount of colonies was reduced to about 78% by 10 nM and to 69% by 100 nM of either toxin. A combined application of 10 nM SA2E with a saponin from Gypsophila paniculata reduced the amount of surviving cells to 68%. The results demonstrate the impact of the CTs on OSCC cells and depict that the stem cell assay is suitable to determine the potential of anti-tumor drugs before studies in vivo will be initiated.

Authors

Christopher Bachran

Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany

Iring Heisler

Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany

Diana Bachran

Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany

Katrin Dassler

Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany

Matthias F. Melzig

Freie Universität Berlin, Berlin, Germany

Jürgen Ervens

Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany

Hendrik Fuchs

Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany


Purchase article for $19

Subscribe to this journal for $129/year